|
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer Clinical research trials and Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer. Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer  Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
For Condition: Stage 4 rectal cancer,liver metastases,stage 4 colon cancer,stage 2 colon cancer,adenocarcinoma of the colon,stage 3 rectal cancer,stage 2 rectal cancer,stage 3 colon cancer,stage 1 colon cancer,stage 1 rectal cancer
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Roswell Park Cancer Institute
Synopsis: RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer. PURPOSE: Clinical trial to study the effectiveness of lymphography in determining the presence or absence of metastatic colorectal cancer in patients.
Details: OBJECTIVES: I. Confirm that injection of isosulfan blue into the mucosa or serosa immediately adjacent to a colorectal cancer results in the lymphatic transport of that agent initially to a specific regional lymph node that can readily be identified on visual inspection, dissected, and histologically evaluated for the presence or absence of metastatic disease. PROTOCOL OUTLINE: All patients receive an injection of isosulfan blue into peritumor serosa upon intraoperative identification of the primary tumor, prior to mesenteric mobilization. If colonoscopy is otherwise indicated, the injection may be delivered to the peritumor mucosa via colonoscopy during the case. The mesentery adjacent to the injection is inspected and the lymphatic pattern and nodes demonstrated by the isosulfan blue are diagrammed and photographed. The sentinel node(s) are surgically dissected and evaluated. If needed, a second injection of isosulfan blue may be given. Prior to mobilization of liver for resection of metastases, isosulfan blue is injected subcapsularly around the metastatic lesion. PROJECTED ACCRUAL: There will be 10 patients accrued into this study.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/75 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Patients must be undergoing surgical resection of a colorectal primary adenocarcinoma - Metastatic colorectal cancer to liver (hepatic metastases) allowed --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 18 to 75 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: No known or suspected allergy to isosulfan blue; Not pregnant
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MiguelRodriguez-Bigas, Study Chair, Roswell Park Cancer Institute
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
Additional Information:
Study ID Numbers: CDR0000066015; RPCI-DS-96-57,NCI-G98-1371
Study Start Date: April 1997
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003186
Other Stage 4 Rectal Cancer Studies:
1. Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
2. Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
3. Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
4. Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed
5. Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
Related Studies:
Other Stage 4 rectal cancer Clinical Trials
Other New York Clinical Trials
Other Buffalo Clinical Trials
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
|
|
|
|
|
|
|
|
